AbbVie Inc (ABBV)vsClearpoint Neuro Inc (CLPT)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
CLPT
Clearpoint Neuro Inc
$11.18
+8.12%
HEALTHCARE · Cap: $353.24M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 165327% more annual revenue ($61.16B vs $36.97M). ABBV leads profitability with a 6.9% profit margin vs -69.1%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CLPT
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+13.1%
Fair Value
$15.39
Current Price
$11.18
$4.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 34.0% year-over-year
Growing faster than its price suggests
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 11.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CLPT
The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 34.0% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : CLPT
The primary concerns for CLPT are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.25 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while CLPT is a hypergrowth play — different risk/reward profiles.
CLPT carries more volatility with a beta of 1.18 — expect wider price swings.
CLPT is growing revenue faster at 34.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Clearpoint Neuro Inc
HEALTHCARE · MEDICAL DEVICES · USA
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?